(Q46542698)

23 December 2017

title

Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy (English)

1 reference

23 December 2017

0 references

1 reference

Allan Lipton

1

1 reference

23 December 2017

Kim Leitzel

2

1 reference

23 December 2017

Suhail M Ali

3

1 reference

23 December 2017

Laurence Demers

4

1 reference

23 December 2017

Harold A Harvey

5

1 reference

23 December 2017

Hilary A Chaudri-Ross

6

1 reference

23 December 2017

Dean Evans

7

1 reference

23 December 2017

Raquel Lang

8

1 reference

23 December 2017

Wolfgang Hackl

9

1 reference

23 December 2017

Peter Hamer

10

1 reference

23 December 2017

Walter Carney

11

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

23 December 2017

published in

Cancer

1 reference

23 December 2017

volume

104

1 reference

23 December 2017

issue

2

1 reference

23 December 2017

page(s)

257-263

1 reference

23 December 2017

Oestrogen receptor: a stable phenotype in breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

Mechanisms of tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Monitoring therapy by serum HER-2/neu

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Serum HER-2/neu and Response to the Aromatase Inhibitor Letrozole Versus Tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R ty

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21202

7 January 2021

Identifiers

DOI

10.1002/CNCR.21202

1 reference

23 December 2017

1 reference

23 December 2017